Beam takes its time to the clinic; Aspen gets clearance to test Parkinson's cell therapy in humans
Over a year and a half since Beam Therapeutics received clearance from the FDA to test its base-edited sickle cell therapy in humans, it has yet to dose a patient.
But Beam insists that it is getting close — in its second quarter report, Beam updated that it has consented enough patients to fill its first cohort of three patients. Beam said it plans to report data from multiple patients in 2024, though it did not specify when it plans to dose its first patient.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
